Market Overview

AVROBIO, Inc. to Present at Chardan's 3rd Annual Genetic Medicines Conference

Share:

AVROBIO, Inc. (NASDAQ:AVRO), a Phase 2 clinical-stage gene therapy company, today announced that Geoff MacKay, President and CEO of AVROBIO, will present at Chardan's 3rd Annual Genetic Medicines Conference on Monday, October 7, 2019.

Chardan's 3rd Annual Genetic Medicines Conference

Date: Monday, October 7, 2019

Time: 3:45 p.m. ET

Location: The Westin Grand Central Hotel, New York, NY

A live webcast of the presentation will be available on the investors section of the AVROBIO company website at www.avrobio.com. After the live webcast, the event will remain archived on the AVROBIO website for 90 days.

About AVROBIO, Inc.

AVROBIO, Inc. is a leading, Phase 2 gene therapy company focused on the development of its investigational gene therapy, AVR-RD-01, in Fabry disease, as well as additional gene therapy programs in other lysosomal storage disorders including Gaucher disease, cystinosis and Pompe disease. The Company's plato™ platform includes a proprietary vector system, automated cell manufacturing solution and refined conditioning regimen deploying therapeutic drug monitoring. AVROBIO is headquartered in Cambridge, MA and has offices in Toronto, ON. For additional information, visit www.avrobio.com.

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com